VRTX — Vertex PharmaceuticalsFREE
Median target
$576
across the calls below
Implied return
+8.5%
median target vs. price
Coverage
34 analysts · 43 calls
within the date window
Consensus
27/6/1+26 net
Buy / Hold / Sell
Current analyst calls on VRTX
Each row is one analyst's live rating and price target. Sorted by implied return by default — click any column header to re-sort. By default only calls updated in the last 12 months are shown — change or clear the bound to see all.
43 of 57 calls shown
| Tazeen Ahmad | – | – | – | Bank of America Securities | Buy | $672 | +26.6% | Aug 10, 2026 | |
| Terence Flynn | – | – | – | Morgan Stanley | Buy | $665 | +25.3% | Sep 1, 2026 | |
| Terence Flynn | – | – | – | Morgan Stanley | Buy | $665 | +25.3% | Sep 22, 2026 | |
| Salveen Richter | – | – | – | Goldman Sachs | Buy | $653 | +23.0% | Sep 22, 2026 | |
| Andrew Fein | – | – | – | H.C. Wainwright | Buy | $641 | +20.8% | Sep 22, 2026 | |
| Akash Tewari | – | – | – | Jefferies | Buy | $640 | +20.6% | Sep 23, 2026 | |
| Eliana Merle | – | – | – | Barclays | Buy | $617 | +16.3% | Sep 23, 2026 | |
| Michael Yee | – | – | – | UBS | Buy | $615 | +15.9% | Sep 28, 2026 | |
| Jeffrey Walch | – | – | – | Bernstein | Buy | $608 | +14.5% | Sep 25, 2026 | |
| William Pickering | – | – | – | Bernstein | Buy | $608 | +14.5% | Aug 11, 2026 | |
| Evan Seigerman | – | – | – | BMO Capital | Buy | $600 | +13.1% | Sep 23, 2026 | |
| Jay Olson | – | – | – | Oppenheimer | Buy | $600 | +13.1% | Mar 10, 2026 | |
| Jay Olson | – | – | – | Oppenheimer | Buy | $600 | +13.1% | May 5, 2026 | |
| Ying Huang | – | – | – | Bank of America Securities | Buy | $598 | +12.7% | Mar 10, 2026 | |
| Carter Gould | – | – | – | Cantor Fitzgerald | Buy | $595 | +12.1% | Aug 4, 2026 | |
| Geoff Meacham | – | – | – | Citi | Buy | $585 | +10.2% | Sep 2, 2026 | |
| Geoff Meacham | – | – | – | Citi | Buy | $585 | +10.2% | Sep 23, 2026 | |
| Michael Yee | – | – | – | UBS | Buy | $585 | +10.2% | Aug 20, 2026 | |
| Brian Abrahams | – | – | – | RBC Capital | Buy | $576 | +8.5% | Oct 8, 2026 | |
| Naz Rahman | – | – | – | Maxim Group | Buy | $575 | +8.3% | Aug 5, 2026 | |
| William Pickering | – | – | – | Bernstein | Buy | $572 | +7.8% | May 5, 2026 | |
| Brian Abrahams | – | – | – | RBC Capital | Buy | $570 | +7.4% | Aug 12, 2026 | |
| Greg Harrison | – | – | – | Scotiabank | Hold | $558 | +5.1% | Feb 13, 2026 | |
| Louise Chen | – | – | – | Scotiabank | Buy | $558 | +5.1% | Sep 23, 2026 | |
| Andy Chen | – | – | – | Wolfe Research | Buy | $557 | +4.9% | Aug 3, 2026 | |
| Mohit Bansal | – | – | – | Wells Fargo | Buy | $550 | +3.6% | Aug 4, 2026 | |
| Mohit Bansal | – | – | – | Wells Fargo | Buy | $550 | +3.6% | Jul 6, 2026 | |
| Phil Nadeau | – | – | – | TD Cowen | Buy | $550 | +3.6% | Aug 4, 2026 | |
| Sadia Rahman | – | – | – | Wells Fargo | Buy | $550 | +3.6% | Jul 13, 2026 | |
| Cory Kasimov | – | – | – | Evercore ISI | Buy | $535 | +0.8% | Aug 4, 2026 | |
| Cory Kasimov | – | – | – | Evercore ISI | Buy | $535 | +0.8% | Jul 7, 2026 | |
| Liisa Bayko | – | – | – | Evercore ISI | Buy | $530 | -0.1% | Jan 23, 2026 | |
| David Risinger | – | – | – | Leerink Partners | Buy | $525 | -1.1% | Dec 29, 2025 | |
| Joon Lee | – | – | – | Truist Financial | Buy | $525 | -1.1% | Mar 11, 2026 | |
| Whitney Ijem | – | – | – | Canaccord Genuity | Hold | $442 | -16.7% | Sep 23, 2026 | |
| Gena Wang | – | – | – | Barclays | Hold | $414 | -22.0% | Nov 10, 2025 | |
| Brian Skorney | – | – | – | Robert W. Baird | Sell | $350 | -34.1% | Jul 7, 2026 | |
| Danielle Brill | – | – | – | Truist Financial | Buy | – | – | Sep 23, 2026 | |
| Hans Engel | – | – | – | Erste Group | Hold | – | – | May 5, 2026 | |
| Joseph Stringer | – | – | – | Needham | Hold | – | – | Aug 4, 2026 | |
| Myles Minter | – | – | – | William Blair | Buy | – | – | Sep 22, 2026 | |
| Paul Matteis | – | – | – | Stifel Nicolaus | Hold | – | – | Sep 22, 2026 | |
| Tazeen Ahmad | – | – | – | Bank of America Securities | Buy | – | – | Sep 29, 2026 |
Analyst track records are Premium — unlock every analyst's score, rank and success rate.
Implied return is the move the stock would make if the analyst's target were hit. These are forward-looking predictions, not realized returns. Only reliable-basis calls are included; the consensus figures above are computed from the calls in this table.
VRTX elsewhere on AnalystEdge
The most recent congressional, executive-branch and insider filings matched to this ticker. Matched by ticker symbol — occasional mismatches are possible. Not investment advice.
Trending today: not in any of today's trending tables (Gaining attention, Losing attention, Most followed)
| Date | Source | Who | Action | Detail | Amount |
|---|---|---|---|---|---|
| 2026-01-30 | Executive | Mody, ArjunDeputy Commissioner | Sale | Vertex Pharmaceuticals, Inc. (VRTX) | $1,001 - $15,000 |
| 2026-01-29 | Congress | David J. TaylorOH-OH02 | Sale | since trade +11.6%, vs market -2.6% | $1K–$15K |
| 2025-06-11 | Congress | Lisa McClainMI-MI09 | Sale | since trade +17.3%, vs market +9.6% | $1K–$15K |
| 2025-06-10 | Congress | Lisa McClainMI-MI09 | Sale | since trade +17.5%, vs market +9.0% | $1K–$15K |
| 2025-03-20 | Congress | Byron DonaldsFL-FL19 | Sale | since trade +4.0%, vs market +31.3% | $1K–$15K |
| 2025-03-20 | Congress | Byron DonaldsFL-FL19 | Sale | since trade +4.0%, vs market +31.3% | $1K–$15K |
| 2025-02-11 | Executive | Duffy, SeanSecretary | Sale | Vertex Pharmaceuticals, Inc. (VRTX) | $1,001 - $15,000 |
| 2025-02-11 | Executive | Duffy, SeanSecretary | Sale | Vertex Pharmaceuticals, Inc. (VRTX) | $1,001 - $15,000 |
| 2024-12-11 | Congress | Lisa McClainMI-MI09 | Purchase | since trade +13.3%, vs market -13.1% | $1K–$15K |
| 2024-10-23 | Congress | Julia LetlowLA-LA05 | Purchase | since trade +12.9%, vs market -19.9% | $1K–$15K |
More: congressional trades on VRTX · insider activity · executive branch · trending